230 related articles for article (PubMed ID: 34168152)
21. [AFP-producing gastric cancer and hepatoid gastric cancer].
Wang YK; Zhang XT
Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):801-807. PubMed ID: 29151285
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive analysis of 19q12 amplicon in human gastric cancers.
Leung SY; Ho C; Tu IP; Li R; So S; Chu KM; Yuen ST; Chen X
Mod Pathol; 2006 Jun; 19(6):854-63. PubMed ID: 16575401
[TBL] [Abstract][Full Text] [Related]
23. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
[TBL] [Abstract][Full Text] [Related]
24. CCNE1 amplification is associated with liver metastasis in gastric carcinoma.
Kim B; Shin HC; Heo YJ; Ha SY; Jang KT; Kim ST; Kang WK; Lee J; Kim KM
Pathol Res Pract; 2019 Aug; 215(8):152434. PubMed ID: 31178228
[TBL] [Abstract][Full Text] [Related]
25. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
[TBL] [Abstract][Full Text] [Related]
26. CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.
Zhao ZM; Yost SE; Hutchinson KE; Li SM; Yuan YC; Noorbakhsh J; Liu Z; Warden C; Johnson RM; Wu X; Chuang JH; Yuan Y
BMC Cancer; 2019 Jan; 19(1):96. PubMed ID: 30665374
[TBL] [Abstract][Full Text] [Related]
27. Muscle RAS oncogene homolog (MRAS) recurrent mutation in Borrmann type IV gastric cancer.
Yasumoto M; Sakamoto E; Ogasawara S; Isobe T; Kizaki J; Sumi A; Kusano H; Akiba J; Torimura T; Akagi Y; Itadani H; Kobayashi T; Hasako S; Kumazaki M; Mizuarai S; Oie S; Yano H
Cancer Med; 2017 Jan; 6(1):235-244. PubMed ID: 27891760
[TBL] [Abstract][Full Text] [Related]
28. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response.
Wang R; Song S; Harada K; Ghazanfari Amlashi F; Badgwell B; Pizzi MP; Xu Y; Zhao W; Dong X; Jin J; Wang Y; Scott A; Ma L; Huo L; Vicente D; Blum Murphy M; Shanbhag N; Tatlonghari G; Thomas I; Rogers J; Kobayashi M; Vykoukal J; Estrella JS; Roy-Chowdhuri S; Han G; Zhang S; Mao X; Song X; Zhang J; Gu J; Johnson RL; Calin GA; Peng G; Lee JS; Hanash SM; Futreal A; Wang Z; Wang L; Ajani JA
Gut; 2020 Jan; 69(1):18-31. PubMed ID: 31171626
[TBL] [Abstract][Full Text] [Related]
29. A 50-Year-Old Man with Fulminant Alpha-Fetoprotein-Producing Gastric Carcinoma and Disseminated Intravascular Coagulation.
Longo R; Carassou P; Leguay C; Basin S; Thiebaut V; Paraschiv EA; Enea AM
Am J Case Rep; 2021 Mar; 22():e928369. PubMed ID: 33667215
[TBL] [Abstract][Full Text] [Related]
30. Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets.
Qian Z; Zhu G; Tang L; Wang M; Zhang L; Fu J; Huang C; Fan S; Sun Y; Lv J; Dong H; Gao B; Su X; Yu D; Zang J; Zhang X; Ji J; Ji Q
Genes Chromosomes Cancer; 2014 Nov; 53(11):883-94. PubMed ID: 24935174
[TBL] [Abstract][Full Text] [Related]
31. HER2 is frequently overexpressed in hepatoid adenocarcinoma and gastric carcinoma with enteroblastic differentiation: a comparison of 35 cases to 334 gastric carcinomas of other histological types.
Fujimoto M; Matsuzaki I; Nishino M; Iwahashi Y; Warigaya K; Kojima F; Ono K; Murata SI
J Clin Pathol; 2018 Jul; 71(7):600-607. PubMed ID: 29305518
[TBL] [Abstract][Full Text] [Related]
32. Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer.
Chen Z; Huang W; Tian T; Zang W; Wang J; Liu Z; Li Z; Lai Y; Jiang Z; Gao J; Shen L
J Hematol Oncol; 2018 Feb; 11(1):20. PubMed ID: 29433585
[TBL] [Abstract][Full Text] [Related]
33. Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients.
Kim ST; Banks KC; Pectasides E; Kim SY; Kim K; Lanman RB; Talasaz A; An J; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Park SH; Park JO; Park YS; Lim HY; Kim NKD; Park W; Lee H; Bass AJ; Kim K; Kang WK; Lee J
Ann Oncol; 2018 Apr; 29(4):1037-1048. PubMed ID: 29409051
[TBL] [Abstract][Full Text] [Related]
34. Decreased expression of claudin-18.2 in alpha-fetoprotein-producing gastric cancer compared to conventional gastric cancer.
Weng W; Zhang M; Ni S; Tan C; Xu M; Wang X; Sun H; Wang L; Huang D; Sheng W
J Gastrointest Oncol; 2022 Jun; 13(3):1035-1045. PubMed ID: 35837176
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive Analysis of Genomic Alterations in Hepatoid Adenocarcinoma of the Stomach and Identification of Clinically Actionable Alterations.
Zhao R; Li H; Ge W; Zhu X; Zhu L; Wan X; Wang G; Pan H; Lu J; Han W
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010842
[TBL] [Abstract][Full Text] [Related]
36. Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in fallopian tube carcinoma.
Snijders AM; Nowee ME; Fridlyand J; Piek JM; Dorsman JC; Jain AN; Pinkel D; van Diest PJ; Verheijen RH; Albertson DG
Oncogene; 2003 Jul; 22(27):4281-6. PubMed ID: 12833150
[TBL] [Abstract][Full Text] [Related]
37. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
Liu YJ; Shen D; Yin X; Gavine P; Zhang T; Su X; Zhan P; Xu Y; Lv J; Qian J; Liu C; Sun Y; Qian Z; Zhang J; Gu Y; Ni X
Br J Cancer; 2014 Mar; 110(5):1169-78. PubMed ID: 24518603
[TBL] [Abstract][Full Text] [Related]
38. Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer.
Noske A; Brandt S; Valtcheva N; Wagner U; Zhong Q; Bellini E; Fink D; Obermann EC; Moch H; Wild PJ
Oncotarget; 2017 Feb; 8(9):14794-14805. PubMed ID: 27582547
[TBL] [Abstract][Full Text] [Related]
39. Integrated paired-end enhancer profiling and whole-genome sequencing reveals recurrent
Ooi WF; Nargund AM; Lim KJ; Zhang S; Xing M; Mandoli A; Lim JQ; Ho SWT; Guo Y; Yao X; Lin SJ; Nandi T; Xu C; Ong X; Lee M; Tan AL; Lam YN; Teo JX; Kaneda A; White KP; Lim WK; Rozen SG; Teh BT; Li S; Skanderup AJ; Tan P
Gut; 2020 Jun; 69(6):1039-1052. PubMed ID: 31542774
[TBL] [Abstract][Full Text] [Related]
40. Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets.
Lyu J; Song Z; Chen J; Shepard MJ; Song H; Ren G; Li Z; Guo W; Zhuang Z; Shi Y
J Pathol; 2018 Mar; 244(3):358-366. PubMed ID: 29230811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
